To prevent further development of antibacterial resistance it is recommended that fluoroquinolones be reserved for treatment of:

Rationale: A. Fluoroquinolones like levofloxacin are considered "respiratory quinolones" and should be reserved for complicated community-acquired pneumonia where traditional therapies might fail. Restricting their use to high-risk patients with comorbidities helps preserve their efficacy against resistant Streptococcus pneumoniae. This targeted approach is a cornerstone of antimicrobial stewardship designed to prevent the emergence of multidrug-resistant bacterial strains in the community. B. Most upper respiratory infections in adults are viral in origin and do not require antibacterial intervention. Using fluoroquinolones for viral colds or uncomplicated bronchitis contributes significantly to the development of bacterial resistance and exposes patients to unnecessary risks like tendon rupture. Guidelines strongly discourage the use of these potent broad-spectrum agents for self-limiting conditions that do not have a confirmed bacterial etiology. C. Fluoroquinolones are no longer recommended as first-line treatment for gonorrhea due to widespread resistance developed by Neisseria gonorrhoeae. Current CDC guidelines prioritize cephalosporins as the primary treatment to ensure effective eradication of the infection. Continuing to use quinolones for this purpose would likely result in treatment failure and the further spread of resistant sexually transmitted infections. D. For uncomplicated urinary tract infections in young women, first-line agents like nitrofurantoin or trimethoprim-sulfamethoxazole are preferred over fluoroquinolones. The FDA has advised that the serious side effects associated with quinolones generally outweigh the benefits for simple infections. Reserving these drugs for more complex or resistant cases is essential to maintain their clinical utility for life-threatening systemic infections.